DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences […]

BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe.  Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs).  “This transaction increases BioIVT’s global operations by adding new clinical collection sites, which are predominantly hospital based, focused on oncology, […]

William Erhardt, President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases.  New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy […]

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. Dr Tralau-Stewart has over 20 years’ senior academic and industry leadership experience and joins ValiRx from drug discovery company C4X Discovery. At C4X Discovery Dr Tralau-Stewart was CSO and managed […]

An update on the latest Covid-19 news by DDW Digital Content Editor Diana Spencer  With winter around the corner and cases once again on the rise, the last few weeks have seen some interesting developments related to Covid-19. We found out that Omicron infection protects against flu, studies in potential treatments for severe Covid have […]

The US Food and Drug Administration (FDA) has granted approval to AMX0035, a new treatment for people living with amyotrophic lateral sclerosis (ALS). Development of the drug was funded by $2.2 million from the ALS Association, raised by the 2014 social media craze the ‘Ice Bucket Challenge’. Another 40 potential new treatments are being investigated.  […]

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in increased antibody-dependent cellular cytotoxicity (ADCC). […]

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in increased antibody-dependent cellular cytotoxicity (ADCC). […]

Join DDW for this exclusive free event High resolution electron cryo-microscopy: From membrane proteins to diseases, supported by Thermo Fisher Scientific, will take place on 19 October, 2022, 4PM BST, 8AM PDT. Discover how cryo-EM is impacting high resolution structure biology from membrane proteins to diseases including Alzheimer’s disease and cancer therapeutics by showing high-resolution structures of […]

Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Register now to attend the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Key […]